<DOC>
	<DOCNO>NCT01998971</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , dose regimen daratumumab administer combination various treatment regimen treatment multiple myeloma .</brief_summary>
	<brief_title>A Study JNJ-54767414 ( HuMax CD38 ) ( Anti-CD38 Monoclonal Antibody ) Combination With Backbone Treatments Treatment Patients With Multiple Myeloma</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) study evaluate safety , tolerability , dose daratumumab administer combination various treatment regimen different setting multiple myeloma . The various treatment regimen combine daratumumab study include Velcade-dexamethasone ( VD ) , Velcade-melphalan-prednisone ( VMP ) , Velcade-thalidomide-dexamethasone ( VTD ) , pomalidomide-dexamethasone ( Pom-dex ) , carfilzomib-dexamethasone ( CFZ-dex ) carfilzomib-lenalidomide-dexamethasone ( KRd ) . Approximately 250 patient ( approximately 12 subject per VTD VMP backbone treatment regimen , 6 VD regimen , 100 subject Pom-dex regimen , 80 CFZ-dex regimen [ 10 subject receive single-dose daratumumab remain subject receive split-dose daratumumab ] , 40 KRd regimen ) enrol study.The study consist screening , treatment , follow-up phase . Treatment extend either plan treatment duration maximum 1 year ( Velcade-dexamethasone , Velcade-melphalan-prednisone , Velcade-thalidomide-dexamethasone regimen KRd regimen ) , disease progression ( Pom-dex CFZ-dex regimen ) . Follow-up continue study end ( approximately 15 month last patient receives first dose daratumumab ) . Serial pharmacokinetic ( study drug body ) blood sample collect . Clinical efficacy outcome safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Confirmed diagnosis symptomatic multiple myeloma measurable secretory disease For carfilzomiblenalidomidedexamethasone ( KRd ) regimen : newly diagnose myeloma . For carfilzomibdexamethasone ( CFZdex ) regimen : relapse refractory disease Eastern Cooperative Oncology Group performance status score 0 , 1 , 2 Pretreatment clinical laboratory value must meet protocoldefined parameter screen phase Previously receive daratumumab antiCD38 therapy Diagnosis primary amyloidosis , monoclonal gammopathy undetermined significance , smolder multiple myeloma , Waldenstr√∂m 's disease , condition IgM Mprotein present absence clonal plasma cell infiltration lytic bone lesion Peripheral neuropathy neuropathic pain Grade 2 high Prior concurrent invasive malignancy ( multiple myeloma ) within 5 year study start Exhibiting clinical sign meningeal involvement multiple myeloma Known chronic obstructive pulmonary disease , persistent asthma , history asthma within 2 year Seropositive human immunodeficiency virus , hepatitis B , hepatitis C Any concurrent medical psychiatric condition disease likely interfere study procedure result , opinion investigator , would constitute hazard participate study Clinically significant cardiac disease Plasma cell leukemia POEMS ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Daratumumab</keyword>
	<keyword>JNJ-54767414</keyword>
	<keyword>Velcade-dexamethasone</keyword>
	<keyword>Velcade-melphalan-prednisone</keyword>
	<keyword>Velcade-thalidomide-dexamethasone</keyword>
	<keyword>Pomalidomide-dexamethasone</keyword>
	<keyword>Carfilzomib-dexamethasone</keyword>
	<keyword>Carfilzomib-lenalidomide-dexamethasone</keyword>
	<keyword>Anti-CD38 Monoclonal Antibody</keyword>
	<keyword>Immunomodulatory drug</keyword>
	<keyword>IMiD</keyword>
</DOC>